{"description":"Only participant-volunteered side effects were noted.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":48,"description":"Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.\n\nbupropion hydrochloride: Given orally\n\nplacebo: Given orally","id":"EG000","otherNumAffected":48,"otherNumAtRisk":48,"seriousNumAffected":0,"seriousNumAtRisk":48,"title":"Arm I (1-week run-in)"},{"deathsNumAffected":0,"deathsNumAtRisk":47,"description":"Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.\n\nbupropion hydrochloride: Given orally","id":"EG001","otherNumAffected":47,"otherNumAtRisk":47,"seriousNumAffected":0,"seriousNumAtRisk":47,"title":"Arm II (4-week run-in)"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Adverse events (not including serious) only tracked for clinical monitoring; all participants noted at least one adverse event during the 8-week period of monitoring.","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":48,"numAtRisk":48,"numEvents":48},{"groupId":"EG001","numAffected":47,"numAtRisk":47,"numEvents":47}],"term":"Any Non-Serious Adverse Event"}],"timeFrame":"8 weeks"}